000287409 001__ 287409
000287409 005__ 20241111105229.0
000287409 0247_ $$2doi$$a10.3390/ijms25021244
000287409 0247_ $$2pmid$$apmid:38279245
000287409 0247_ $$2pmc$$apmc:PMC10816965
000287409 0247_ $$2ISSN$$a1422-0067
000287409 0247_ $$2ISSN$$a1661-6596
000287409 037__ $$aDKFZ-2024-00224
000287409 041__ $$aEnglish
000287409 082__ $$a540
000287409 1001_ $$aAlmouhanna, Firas$$b0
000287409 245__ $$aAn ESR1-Related Gene Signature Identifies Head and Neck Squamous Cell Carcinoma with Imputed Susceptibility to Endocrine Therapy.
000287409 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2024
000287409 3367_ $$2DRIVER$$aarticle
000287409 3367_ $$2DataCite$$aOutput Types/Journal article
000287409 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1706532130_23420
000287409 3367_ $$2BibTeX$$aARTICLE
000287409 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000287409 3367_ $$00$$2EndNote$$aJournal Article
000287409 500__ $$a#LA:E221#
000287409 520__ $$aHead and neck squamous cell carcinoma (HNSCC) is associated with high morbidity and mortality. New personalized treatment strategies represent an unmet medical need to improve the overall survival and the quality of life of patients, which are often limited by the toxicity of established multimodal treatment protocols. Several studies have reported an increased expression of the estrogen receptor 1 (ESR1) in HNSCC, but its potential role in the disease outcome of these tumors remains elusive. Using an integrative analysis of multiomics and clinical data from The Cancer Genome Atlas (TCGA)-HNSC, we established a prognostic risk model based on an ESR1-related 25-gene set. The prognostic value was confirmed in an independent cohort of HNSCC and other solid tumors from TCGA. Finally, we performed in silico drug sensitivity modeling to explore potential vulnerabilities for both risk groups. This approach predicted a higher sensitivity for HNSCC, with prominent ESR1 pathway activity under treatment with specific estrogen receptor modulators. In conclusion, our data confirm the involvement of ESR1-related pathway activity in the progression of a defined subset of HNSCC, provide compelling evidence that these tumors share a specific vulnerability to endocrine therapy, and pave the way for preclinical studies and clinical trials to demonstrate the efficacy of this new therapeutic option.
000287409 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000287409 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000287409 650_7 $$2Other$$aendocrine therapy
000287409 650_7 $$2Other$$aestrogen receptor alpha
000287409 650_7 $$2Other$$ahead and neck cancers
000287409 650_7 $$2Other$$arisk model
000287409 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b1$$eLast author$$udkfz
000287409 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms25021244$$gVol. 25, no. 2, p. 1244 -$$n2$$p1244$$tInternational journal of molecular sciences$$v25$$x1422-0067$$y2024
000287409 8564_ $$uhttps://inrepo02.dkfz.de/record/287409/files/ijms-25-01244.pdf
000287409 8564_ $$uhttps://inrepo02.dkfz.de/record/287409/files/ijms-25-01244.pdf?subformat=pdfa$$xpdfa
000287409 909CO $$ooai:inrepo02.dkfz.de:287409$$pVDB
000287409 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000287409 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000287409 9141_ $$y2024
000287409 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000287409 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000287409 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
000287409 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-07T16:31:47Z
000287409 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-25
000287409 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-25
000287409 9202_ $$0I:(DE-He78)E221-20160331$$kE221$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000287409 9201_ $$0I:(DE-He78)E221-20160331$$kE221$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000287409 980__ $$ajournal
000287409 980__ $$aVDB
000287409 980__ $$aI:(DE-He78)E221-20160331
000287409 980__ $$aUNRESTRICTED